Trial Profile
An Exploratory Pharmacokinetic, Pharmacodynamic and Safety Study of XP21279 (With Lodosyn) and Sinemet in Parkinson's Disease Subjects With Motor Fluctuations.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 May 2021
Price :
$35
*
At a glance
- Drugs XP 21279 (Primary) ; Carbidopa; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors XenoPort
- 30 Apr 2021 Number of treatment arms increased from 1 to 2, the two arms being designated as Active Comparator: Treatment Period A comprising Carbidopa / Levodopa treatment and Experimental: Treatment period B comprising Carbidopa Pill.
- 12 Mar 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
- 12 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.